Replimune Group Inc (REPL) Stock Price, Quote & News

Company Profile

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The c...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 222 9600

Website: www.replimune.com

Address:

500 Unicorn Park Drive, Suite 303, 3rd Floor, Woburn, United States

BioCrazy1 Sep. 4 at 2:55 AM

$REPL A new class action — Toor v. Replimune Group, Inc. et al., Case No. 1:26-cv-13612 (D. Mass.) — was filed around August 6, 2026. Class period is October 20, 2025 – April 10, 2026. Lead-plaintiff deadline is October 5, 2026. AP News Plaintiffs allege Replimune and certain officers made misleading statements / omitted that: FDA study-design concerns from earlier interactions had not been fixed. The resubmission used early, unplanned 40-patient IGNYTE-3 data. Those issues made another rejection likely.

0 · Reply

longDstyle Sep. 3 at 10:26 PM

$REPL this stock is like $HTFL . Manipulated like crazy. Price action is extremely hard to predict

0 · Reply

Comicguy Sep. 3 at 5:42 PM

$REPL What happened

1 · Reply

focafoca99 Sep. 3 at 2:31 PM

$REPL warns investors of a pending securities class action over alleged misstatements after FDA rejection.

1 · Reply

Diefreeandsell Sep. 3 at 12:54 PM

$REPL Well it's now after the offering and $BMY is still in play to be Buyer with $JPM handling it. I was wrong about $GS doing the deal. Anyways it's being supported by about $4 over the offering price from Aug. Pretty good . $BMY get's to use that cash for ro9llout and sales team when BO is announced by end of Sept-Early Oct imo. Nice to see that $XBI is holding up as well with it's breakout after so many years of dismal performance.

0 · Reply

Amb8675309 Sep. 2 at 10:40 PM

$RARE bought at the bottom- these often recover- could be quick- could be months, but they do: not debating value of specific drug- just that the over reaction to bad news is something that’s been working for me- it’s just hard to run into a burning building $MIST, $ GUTS( bought in the $.40’s), $REPL, plus a couple others

0 · Reply

DRAM27 Sep. 2 at 7:55 PM

$REPL Easy money!!! If tutes are filling ATM up here we're golden. $20 This month if we're not bought out for $50 per share !!! 🚀🚀🚀🚀

1 · Reply

History101 Sep. 2 at 7:04 PM

$REPL $SLS $BIAF I love days like today when my portfolios are up over 3%, crushing the market. GLTALs!!

0 · Reply

History101 Sep. 2 at 6:50 PM

$REPL added. again.

0 · Reply

History101 Sep. 2 at 6:41 PM

$REPL REPL cannot be over $16 now, no way. The shorts said REPL was going to $9. The market must be mistaken....

2 · Reply

Replimune to Present at the Cantor Global Healthcare Conference 2026

Sep 1, 2026, 10:19 AM EDT - 2 days ago

SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. Lawsuit - REPL

2026-08-26T11:30:16.000Z - 8 days ago

Replimune price target raised to $21 from $20 at JPMorgan

Aug 25, 2026, 4:07 PM EDT - 9 days ago

REPL Stockholders Have Rights – If You Lost Money Investing in Replimune Group, Inc. Contact Robbins LLP for Information About Recovering Your Losses

Aug 19, 2026, 4:01 PM EDT - 15 days ago

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-08-16T12:38:32.000Z - 18 days ago

Replimune files automatic mixed securities shelf

Aug 14, 2026, 8:00 AM EDT - 20 days ago

Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update

Aug 14, 2026, 7:00 AM EDT - 20 days ago

Replimune Group Earnings release: Q1 2027

Aug 14, 2026, 7:00 AM EDT - 20 days ago

Replimune Group Quarterly report: Q1 2027

Aug 13, 2026, 12:37 PM EDT - 21 days ago

SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. Lawsuit - REPL

Aug 10, 2026, 8:00 AM EDT - 24 days ago

Replimune Announces Pricing of $150 Million Underwritten Offering

Aug 7, 2026, 12:36 PM EDT - 27 days ago

Replimune Wins FDA Skin Cancer Drug Approval on Third Try. Why the Stock Is Tumbling.

2026-08-07T12:02:14.000Z - 27 days ago

Replimune price target raised to $20 from $16 at BMO Capital

2026-08-07T10:31:49.000Z - 27 days ago

Wedbush upgrades Replimune to Outperform following FDA decision

2026-08-07T10:27:08.000Z - 27 days ago

Replimune upgraded to Outperform from Neutral at Wedbush

2026-08-06T21:50:37.000Z - 4 weeks ago

Replimune announces FDA accelerated approval of Tudriqev for advanced melanoma

Aug 6, 2026, 4:30 PM EDT - 4 weeks ago

Replimune Group Transcript: FDA announcement

Aug 6, 2026, 4:30 PM EDT - 4 weeks ago

Replimune Group Press release: FDA announcement

Aug 6, 2026, 4:30 PM EDT - 4 weeks ago

Replimune Group Slides: FDA announcement

Aug 6, 2026, 4:26 PM EDT - 4 weeks ago

US FDA approves Replimune's skin cancer drug

Aug 6, 2026, 4:18 PM EDT - 4 weeks ago

FDA Approves Replimune's Melanoma Drug On Third Attempt

2026-08-04T09:05:14.000Z - 4 weeks ago

Replimune upgraded to Outperform from Market Perform at Leerink

2026-07-31T15:36:59.000Z - 4 weeks ago

Why Is Replimune (REPL) Stock Up Today?

2026-07-31T12:51:02.000Z - 4 weeks ago

Piper upgrades Replimune to Overweight on better odds of RP1 approval

2026-07-31T12:45:48.000Z - 4 weeks ago

Replimune upgraded to Overweight from Neutral at Piper Sandler

Jul 31, 2026, 8:37 AM EDT - 4 weeks ago

This Biotech Stock Is Soaring 132% After Key FDA Panel Vote on Skin Cancer Treatment

2026-07-31T12:25:20.000Z - 4 weeks ago

Replimune price target raised to $12 from $9 at Wedbush

2026-07-31T10:31:14.000Z - 4 weeks ago

Why is Biotech Stock Replimune (REPL) Soaring Over 120% Today?

BMY

Jul 31, 2026, 5:40 AM EDT - 4 weeks ago

Replimune surges after FDA advisers back skin cancer drug

2026-07-31T08:55:19.000Z - 4 weeks ago

Replimune upgraded to Overweight from Neutral at Cantor Fitzgerald

Jul 30, 2026, 6:15 PM EDT - 5 weeks ago

Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma

Jul 30, 2026, 5:27 PM EDT - 5 weeks ago

A Food and Drug Administration advisory panel voted 10-3 for Replimune Group's experimental melanoma therapy, after experts raised doubts about whether the company's data and trial design could be trusted to show the drug works

Jul 30, 2026, 5:10 PM EDT - 5 weeks ago

US FDA panel backs Replimune skin cancer drug study data

Jul 30, 2026, 7:00 AM EDT - 5 weeks ago

Replimune Group Slides: Investor presentation

Jul 29, 2026, 8:00 AM EDT - 5 weeks ago

Replimune Group Proxy statement: Proxy filing

Jul 29, 2026, 8:00 AM EDT - 5 weeks ago

Replimune Group Proxy statement: Proxy filing

Jul 28, 2026, 6:21 PM EDT - 5 weeks ago

Replimune Group, Inc. (REPL) Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel Following FDA Briefing Document

Jul 28, 2026, 7:47 AM EDT - 5 weeks ago

US FDA staff raise efficacy concerns on Replimune's skin cancer drug ahead of meeting

Jul 24, 2026, 8:00 AM EDT - 5 weeks ago

Replimune Group Registration statement: Registration filing

Jul 15, 2026, 11:28 AM EDT - 7 weeks ago

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Replimune Group, Inc. (REPL)

Jul 13, 2026, 8:00 AM EDT - 7 weeks ago

Replimune Group Proxy statement: Proxy filing

Jun 29, 2026, 8:00 AM EDT - 2 months ago

Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update

Jun 29, 2026, 8:00 AM EDT - 2 months ago

Replimune Group Earnings release: Q4 2026

Jun 29, 2026, 8:00 AM EDT - 2 months ago

Replimune Group Annual report: Q4 2026

Jun 26, 2026, 8:00 AM EDT - 2 months ago

Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma

May 31, 2026, 8:00 AM EDT - 3 months ago

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

May 30, 2026, 8:00 AM EDT - 3 months ago

Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

May 29, 2026, 9:53 PM EDT - 3 months ago

How Replimune's drug got a third chance after the White House intervened

May 29, 2026, 8:51 AM EDT - 3 months ago

Replimune to resubmit twice-rejected drug for approval after FDA shakeup

May 29, 2026, 8:07 AM EDT - 3 months ago

Replimune reaches agreement with US FDA to resubmit melanoma drug application

May 29, 2026, 8:00 AM EDT - 3 months ago

Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA

May 29, 2026, 7:30 AM EDT - 3 months ago

Replimune Gets Third Try at FDA Approval After Makary Departure

May 5, 2026, 10:58 AM EDT - 4 months ago

FDA Commissioner Makary defends agency's decision on Replimune's drug

Apr 22, 2026, 12:56 PM EDT - 4 months ago

US Health Secretary Kennedy distances himself from FDA's Replimune cancer drug rejection

Apr 13, 2026, 11:46 AM EDT - 4 months ago

Replimune co-founder calls FDA rejection of melanoma drug ‘unfair'

Apr 10, 2026, 5:02 PM EDT - 4 months ago

Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma

Apr 10, 2026, 11:24 AM EDT - 4 months ago

US FDA declines to approve Replimune's drug for advanced skin cancer

Mar 9, 2026, 2:20 PM EDT - 5 months ago

Replimune Group Transcript: Leerink Global Healthcare Conference 2026

Mar 2, 2026, 8:00 AM EST - 6 months ago

Replimune to Present at Two Upcoming Investor Conferences

Feb 3, 2026, 8:00 AM EST - 7 months ago

Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update

Feb 3, 2026, 8:00 AM EST - 7 months ago

Replimune Group Quarterly report: Q3 2026

Feb 3, 2026, 8:00 AM EST - 7 months ago

Replimune Group Earnings release: Q3 2026

Jan 14, 2026, 4:30 PM EST - 7 months ago

Replimune Group Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 4:30 PM EST - 7 months ago

Replimune Group Slides: 44th Annual J.P. Morgan Healthcare Conference

Dec 18, 2025, 8:00 AM EST - 8 months ago

Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference

Nov 7, 2025, 4:45 PM EST - 10 months ago

Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)

Nov 6, 2025, 8:30 AM EST - 10 months ago

Replimune Group Earnings release: Q2 2026

Nov 6, 2025, 8:30 AM EST - 10 months ago

Replimune Group Quarterly report: Q2 2026

Nov 6, 2025, 8:00 AM EST - 10 months ago

Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update

Nov 6, 2025, 7:00 AM EST - 10 months ago

Replimune Group Registration statement: Registration Filing

Oct 20, 2025, 7:00 AM EDT - 10 months ago

Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma

Oct 19, 2025, 8:00 AM EDT - 10 months ago

Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025

BioCrazy1 Sep. 4 at 2:55 AM

0 · Reply

longDstyle Sep. 3 at 10:26 PM

$REPL this stock is like $HTFL . Manipulated like crazy. Price action is extremely hard to predict

0 · Reply

Comicguy Sep. 3 at 5:42 PM

$REPL What happened

1 · Reply

focafoca99 Sep. 3 at 2:31 PM

$REPL warns investors of a pending securities class action over alleged misstatements after FDA rejection.

1 · Reply

Diefreeandsell Sep. 3 at 12:54 PM

0 · Reply

Amb8675309 Sep. 2 at 10:40 PM

0 · Reply

DRAM27 Sep. 2 at 7:55 PM

$REPL Easy money!!! If tutes are filling ATM up here we're golden. $20 This month if we're not bought out for $50 per share !!! 🚀🚀🚀🚀

1 · Reply

History101 Sep. 2 at 7:04 PM

$REPL $SLS $BIAF I love days like today when my portfolios are up over 3%, crushing the market. GLTALs!!

0 · Reply

History101 Sep. 2 at 6:50 PM

$REPL added. again.

0 · Reply

History101 Sep. 2 at 6:41 PM

$REPL REPL cannot be over $16 now, no way. The shorts said REPL was going to $9. The market must be mistaken....

2 · Reply

raylin Sep. 2 at 5:44 PM

$REPL

0 · Reply

Nathan82 Sep. 2 at 1:38 PM

$REPL Look at the weekly chart, price increasing, volume decreasing. This continues to benefit from low volume, no interest manipulation, kept propped up for the next inevitable offering.

0 · Reply

55X_ROI_Q1_2026 Sep. 2 at 5:32 AM

$SLS • 18 Events in 18 Months about 1 Event Per Month ... its now been 3 months 24 Days while we Await 2 .... its Now 114 Days Since the 78th Event was announced - on May 11th. • 60th Occurred Dec 10th 2024 Jan 2023 IDMC Unblinded Actual Phase 3 MOS and IR Data from the INTERIM ANALYSIS -- and the Share PRICE Launched and Market Value Unblinded P3 data told the AML space Gps is Golden. • 72nd Occurred Dec 26th 2025 and the SHARE PRICE LAUNCHED • 78th Occurred May 11 2026 and the SHARE PRICE LAUNCHED * 80th Event is NOW IMMINENT • 18 Events in 18 Months about 1 Event Per Month ... its now been 3 months 24 Days while we Await 2 .... Now is the time BE FULLY LOADED - for when T1 Halts and GAPs UP 1,000% .... Mark This Post. ANY DAY NOW. $MRNA $REPL https://ir.sellaslifesciences.com/news/News-Details/2025/SELLAS-Life-Sciences-Announces-Positive-Outcome-of-Interim-Analysis-for-its-Pivotal-Phase-3-REGAL-Trial-of-GPS-in-Acute-Myeloid-Leukemia/default.aspx

0 · Reply

55X_ROI_Q1_2026 Sep. 1 at 7:33 PM

0 · Reply

55X_ROI_Q1_2026 Sep. 1 at 5:41 PM

1 · Reply

55X_ROI_Q1_2026 Sep. 1 at 5:28 PM

$SLS its Now 114 Days Since the 78th Event was announced - on May 11th. • 60th Occurred Dec 10th 2024 • 72nd Occurred Dec 26th 2025 • 78th Occurred May 11 2026 • 18 Events in 18 Months about 1 Event Per Month ... its now been 3 months 24 Days while we Await 2 .... Now is the time BE FULLY LOADED - for when T1 Halts and GAPs UP 1,000% .... Mark This Post. ANY DAY NOW. $MRNA $REPL

0 · Reply

focafoca99 Sep. 1 at 2:35 PM

$REPL communicated a lead plaintiff deadline of Oct 5, 2026 for the securities class action.

0 · Reply

SeniorVip Aug. 31 at 7:45 PM

$REPL The revenue will be coming in about 1 month from now. Potential revenue per year is $600M-$1.5B. The market cap of the company should climb to $15B or 10X from where it is right now.

1 · Reply

Moathalkhteeb1122 Aug. 30 at 5:12 PM

$TENX huge news pree market pop 100%+ $REPL : $1.55 → $15+ 📈 $CAPR : ~$3 → ~$10 📈 Both collapsed hard, then staged massive rebounds after major catalysts changed the market’s view. $TENX : ~$15 → ~$2 🚀 HUGE NEWS Could $TENX be next? 👀🚀👇🏼

0 · Reply

Moathalkhteeb1122 Aug. 30 at 5:09 PM

$TENX $REPL : $1.55 → $15+ 📈 $CAPR : ~$3 → ~$10 📈 Both collapsed hard, then staged massive rebounds after major catalysts changed the market’s view. $TENX : ~$15 → ~$2 🚀 HUGE NEWS Could $TENX be next? 👀🚀👇🏼

0 · Reply

History101 Aug. 29 at 12:58 AM

$REPL How is REPL at $15.45?? LOL....

0 · Reply

RexColbrook Aug. 28 at 5:13 PM

$REPL 🤷‍♂️

0 · Reply

Market Cap	1.50B
Revenue (ttm)	0.00
Net Income (ttm)	-313.94M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.80

Volume	1,353,600
Avg Vol	5,060,920
Day's Range	N/A - N/A
Shares Out	93.80M
Stochastic %K	53%
Beta	0.94
Analysts	Strong Sell
Price Target	$19.50